Certains contenus de cette application ne sont pas disponibles pour le moment.
Si cette situation persiste, veuillez nous contacter àObservations et contact
1. (WO2018225087) COMPLEXES DE COBALT, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

WE CLAIM:

1. A cobalt complex compound represented by the general formula (I),


Wherein, X is selected from the group consisting of halides; pseudohalides; anionic ligands selected from CN", H , RS", RO ;

R = R1 or R≠ R1 and Both R and R1 are same or different, straight or branched and represents independently of each other hydrogen, or (un)substituted or substituted alkyl, alkenyl or alkynyl; or (un)substituted or substituted aryl, heteroalkyl, heteroaryl, arylalkyl, heteroarylalkyl; (un) substituted or substituted cycloalkyls, cycloalkenyl or cycloalkynyl; azo, amino, halo, nitro, cyano, hydroxyl, carbonyl, thiocarbonyl, carboxylic, ester, alkoxy, alkylamino, arylaminocarbamide, carbamate, hydrazine, sulfonyl, sulphide, thioether, sulphonamide, phosphates

R represents hydrogen, or (un)substituted or substituted alkyl, alkenyl or alkynyl; or (un)substituted or substituted aryl, heteroalkyl, heteroaryl, arylalkyl, heteroarylalkyl; (un) substituted or substituted cycloalkyls, cycloalkenyl or cycloalkynyl; azo, amino, halo, nitro, cyano, hydroxyl, carbonyl, thiocarbonyl, carboxylic, ester, alkoxy, alkylamino, arylaminocarbamide, carbamate, hydrazine, sulfonyl, sulphide, thioether, sulphonamide, phosphates.

2. The compound as claimed in claim 1, wherein the compound of formula (I) is selected from Cobalt(II)(2,6-bis((4-methylpiperazin-l-yl)methyl)pyridine)chloride (1A), Cobalt(II)(2,6-bis(piperazin-l-ylmethyl)pyridine)chloride (IB), Cobalt(II)(2,6- bis(morpholinomethyl)pyridine)chloride (1C), Cobalt(II)(2,6-bis(piperidin-l- ylmethyl)pyridine)chloride (ID), Cobalt(II)(2,6-bis((4-methylpiperazin- 1- yl)methyl)pyridine)bromide (2A), Cobalt(II)(2,6-bis(piperazin-l-ylmethyl)pyridine) bromide (2B), Cobalt(II)(2,6-bis(morpholinomethyl)pyridine)bromide (2C) or Cobalt(II)(2,6-bis(piperidin-l-ylmethyl)pyridine)bromide (2D).

3. A process for the synthesis of compounds of formula (I) comprising the steps of:

a) Adding a solution of 2,6-bis(bromomethyl)pyridine in acetonitrile to a solution of amine and base in solvent followed by stirring at a temperature in the range of 80 to 90°C for the period in the range of 14 to 16 hours to afford NNN-Ligand; b) Adding a solution of Cobalt halo hexahydrate in solvent to a solution of NNN- Ligand of step (a) in solvent with stirring for 3 to 4 hours at the temperature range of 25 to 30° C to afford the desired product of formula (I).

4. The process as claimed in claim 3, wherein said base is selected from group consisting of potassium carbonate, sodium carbonate, lithium carbonate, caesium carbonate, sodium hydride, cesium fluoride, tripotasium phosphate , monopotassium phosphate or potassium bicarbonate.

5. The process as claimed in claim 3, wherein said amine is selected from group consisting of morpholine, piperidine or 1-methylpiperazine, and any secondary and primary amines with chiral and achiral version.

6. The process as claimed in claim 3, wherein said solvent is selected from group consisting of methanol, acetonitrile, ethanol, dimethylformamide , dimethyl sulfoxide, isopropyl alcohol or tetrahydrofuran.

7. A pharmaceutical composition comprising a compound of formula (I), or a stereoisomer, or ester or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent or excipient.

8. A method for Inhibition of Tau Aggregation in a subject in need thereof; comprising administering to the subject a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof.

9. A process for the selective hydrogenation of alkenes or alkynes in the presence of cobalt compound of formula (I) as catalysts comprises mixing alkyne/alkene, amino- borane, cobalt complex and methanol followed by stirring for the period in the range of 10 to 14 h at a temperature range of 50 to 80 °C to obtain the desired alkene/alkane.

10. The process as claimed in claim 9, wherein said alkyne is selected from group consisting of internal alkyne or terminal alkyne; said alkene is selected from terminal alkene; and said cobalt complex is selected from compounds 1A, IB, 1C, ID, 2A, 2B, 2C or 2D.